Muralikrishna M Duvvuri

US Patent:

20100029585, Feb 4, 2010

Filed:

Jul 31, 2009

Appl. No.:

12/533596

Inventors:

J. Jeffry Howbert - Bellevue WA, US
Muralikrishna Duvvuri - Durham NC, US
Robert Hershberg - Seattle WA, US
Gregory Dietsch - Snohomish WA, US

International Classification:

A61K 31/724
A61P 35/00

US Classification:

514 58

Abstract:

The present invention is directed generally to stable formulations of a TLR agonist preferably a TLR7 or a TLR8 agonist, for use in the treatment of cancer, preferably solid tumors and lymphomas. Specifically, the present invention is directed to stable formulations of up to 50 mg/ml of a TLR agonist which comprise a cyclodextrin.

US Patent:

20130018042, Jan 17, 2013

Filed:

Jul 16, 2012

Appl. No.:

13/550192

Inventors:

J. Jeffry Howbert - Redmond WA, US
Muralikrishna Duvvuri - Durham NC, US
Robert Hershberg - Seattle WA, US
Gregory Dietsch - Snohomish WA, US

International Classification:

A61K 31/55
A61P 31/00
A61P 17/00
A61P 35/00

US Classification:

51421701

Abstract:

The present invention is directed generally to stable formulations of a TLR agonist preferably a TLR7 or a TLR8 agonist, for use in the treatment of cancer, preferably solid tumors and lymphomas. Specifically, the present invention is directed to stable formulations of up to 50 mg/ml of a TLR agonist which comprise a cyclodextrin.

US Patent:

20200054615, Feb 20, 2020

Filed:

Mar 12, 2018

Appl. No.:

16/492804

Inventors:

- Sudbury MA, US
Muralikrishna Duvvuri - Chapel Hill NC, US
Parag M. Ved - Lutz FL, US
Bruce Rehlaender - Lake Oswego OR, US
Jay Breaux - Chapel Hill NC, US
Winston A. Vadino - Whitehouse Station NJ, US
Kripanath Borah - Stewartsville NJ, US
Carol Gloff - Natick MA, US

International Classification:

A61K 31/444
A61K 31/5513
A61K 9/48
A61K 9/28
A61K 9/24

Abstract:

Provided are pharmaceutical compositions useful for the treatment and/or prevention of a disorder, such as addiction. For example, pharmaceutical compositions are provided that comprise a first active pharmaceutical component (e.g., metyrapone) and a second active pharmaceutical component (e.g., oxazepam). The compositions may be constructed in such a manner as to limit the physical contact between the first and second active pharmaceutical components, thus preventing any degradation of the active pharmaceutical components resulting form interaction between the two components. The compositions may include at least one pharmaceutically acceptable excipient. Also provided are methods of making the compositions as well as kits containing materials to provide the compositions.

US Patent:

20160331758, Nov 17, 2016

Filed:

Dec 21, 2015

Appl. No.:

14/977129

Inventors:

- Seattle WA, US
Muralikrishna Duvvuri - Durham NC, US
Robert Hershberg - Seattle WA, US
Gregory Dietsch - Snohomish WA, US

International Classification:

A61K 31/55
A61K 47/40

Abstract:

The present invention is directed generally to stable formulations of a TLR agonist preferably a TLR7 or a TLR8 agonist, for use in the treatment of cancer, preferably solid tumors and lymphomas. Specifically, the present invention is directed to stable formulations of up to 50 mg/ml of a TLR agonist which comprise a cyclodextrin.